Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone.

Giuseppe Salemi, Giovanni Savettieri, Paolo Ragonese, Mancardi, Pesci, Barbara Palmeri, Mariemma Rodegher, Cinzia Cordioli, Rizzo, Servillo, Masera, Lorefice, Laisa, Iaffaldano, Hakiki, Marta Radaelli, Coghe, Rinaldi, Giovanna De Luca, StraffiAusili Cefaro, Rasia, Guareschi, Simone, Marco Salvetti, Bianca, Bergamaschi, Cusimano, Iudice, Alfieri, Valentina Zipoli, Lucia Moiola, Frau, Stecchi, De Rossi, Maura, Barreca, Vidali, Spitalieri, Giro, Tommaso, Gallo, Patrizia Sola, Scarpini, Ruggieri, Piras, Dattola, Portaccio, Bellantonio, Marchello, Maria Buccafusca, Ponzio, Ticca, Gaetano Vitello, Lus, Lucchese, Simona Malucchi, Motti, Di Sapio, Rottoli, Bartolozzi, Cavalla, Baldini, Maimone, Florio, Paolo Ragonese, Buttinelli, Galgani, Granella, Galeotti, Perini, Cocco, Guido Cavaletti, Piras, Claudio Solaro, Lugaresi, Farina, Trojano, La Mantia, Martinelli, Claudio Gasperini, Ghezzi, Fantozzi, Scandellari, Capra, Pozzilli, Giovanni Savettieri, Antonio Bertolotto, Zaffaroni, Marrosu, Montanari, Luigi M.E. Grimaldi, Patti, Provinciali, Fabrizio Esposito, Sacco, Colombo, Gioacchino Tedeschi, Maria Pia Amato, Comi, Rossi, Tavazzi, Marco Capobianco

Risultato della ricerca: Article

52 Citazioni (Scopus)

Abstract

OBJECTIVES: To evaluate the incidence and dose-dependency of mitoxantrone (MTX)-associated acute myelocytic leukemia (AML) in the network of Italian multiple sclerosis (MS) clinics.METHODS: We performed a multicenter retrospective cohort study of patients treated with MTX in MS centers under the Italian national health care system between 1998 and 2008. Demographic, disease, treatment, and follow-up information were collected using hospital records.RESULTS: Data were available for 3,220 patients (63% women) from 40 Italian centers. Follow-up (mean ± SD) was 49 ± 29 months (range 12-140 months). We observed 30 cases of AML (incidence 0.93% [95% confidence interval 0.60%-1.26%]). The mean cumulative dose was higher in patients with AML (78 vs 65 mg/m(2), p = 0.028). The median interval from the start of therapy to AML diagnosis was longer than expected at 33 months (range 13-84 months); 8 patients (27%) developed AML 4 years or more after the first MTX infusion. The rate of mortality associated with AML was 37%.CONCLUSIONS: This higher than expected risk of AML and related mortality requires that treatment decisions must be made jointly between clinicians and patients who understand their prognosis, treatment options, and treatment-related risks. The now large exposed MS population must be monitored for hematologic abnormalities for at least 6 years from the end of therapy, to ensure the rapid actions needed for early diagnosis and treatment of AML.
Lingua originaleEnglish
pagine (da-a)1887-1895
Numero di pagine9
RivistaNeurology
Volume77
Stato di pubblicazionePublished - 2011

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cita questo

Salemi, G., Savettieri, G., Ragonese, P., Mancardi, Pesci, Palmeri, B., Rodegher, M., Cordioli, C., Rizzo, Servillo, Masera, Lorefice, Laisa, Iaffaldano, Hakiki, Radaelli, M., Coghe, Rinaldi, De Luca, G., ... Capobianco, M. (2011). Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology, 77, 1887-1895.